Literature DB >> 23817151

Clinicians' attitudes toward the use of long-acting injectable antipsychotics.

Ludovic Samalin1, Thomas Charpeaud, Olivier Blanc, Stephan Heres, Pierre-Michel Llorca.   

Abstract

Depot formulations are not widely used in everyday practice. This study aimed to assess psychiatrists' attitudes toward the use of long-acting injectable (LAI) antipsychotics in schizophrenia. We interviewed 113 French psychiatrists about the factors that influenced their prescription of LAI antipsychotics. Multidimensional and cluster analyses were used to detect correlations. The most important factor against the use of LAI antipsychotics is a sufficient estimated compliance with the oral formulation. For first-generation LAI, the main factor is the risk for extrapyramidal symptoms; and for second-generation LAI, it is the unavailability of the equivalent oral formulation. Four factors incite the psychiatrists to prescribe LAI. Two different clusters of patients can also be identified. Most factors influencing the clinicians' attitudes toward the use of LAI antipsychotics are shared in many countries. Conversely, some attitudes related to organizational aspects, particularly the relevance of health care costs, may vary from one country to another.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817151     DOI: 10.1097/NMD.0b013e31829829c4

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  10 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.

Authors:  Jörg Mahlich; Masamichi Nishi; Yoshimichi Saito
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-22

3.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Authors:  Pierre Michel Llorca; Mocrane Abbar; Philippe Courtet; Sebastien Guillaume; Sylvie Lancrenon; Ludovic Samalin
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

Review 4.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

5.  Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.

Authors:  Ludovic Samalin; Marion Garnier; Candy Auclair; Pierre-Michel Llorca
Journal:  Int J Mol Sci       Date:  2016-11-19       Impact factor: 5.923

6.  Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital.

Authors:  Olaniyi Olayinka; Ayotomide Oyelakin; Karthik Cherukupally; Inderpreet Virk; Chiedozie Ojimba; Susmita Khadka; Alexander Maksymenko; Patrice Fouron; Taher Khandaker; Tolu Olupona; Jason Hershberger
Journal:  Psychiatry J       Date:  2019-06-13

7.  The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing.

Authors:  Lefan Jin; Yun Chen; Junli Zhu; Qingzhi Huang; Bin Li; Ying Xu; Rui Xi; Wei Lu
Journal:  Front Public Health       Date:  2021-11-19

Review 8.  Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.

Authors:  John M Kane; Joseph P McEvoy; Christoph U Correll; Pierre-Michel Llorca
Journal:  CNS Drugs       Date:  2021-10-11       Impact factor: 5.749

9.  Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Authors:  Giovanni Ostuzzi; Maria Angela Mazzi; Samira Terlizzi; Federico Bertolini; Andrea Aguglia; Francesco Bartoli; Paola Bortolaso; Camilla Callegari; Mariarita Caroleo; Giuseppe Carrà; Mariangela Corbo; Armando D'Agostino; Chiara Gastaldon; Claudio Lucii; Fabio Magliocco; Giovanni Martinotti; Michela Nosé; Edoardo Giuseppe Ostinelli; Davide Papola; Marco Piero Piccinelli; Alberto Piccoli; Marianna Purgato; Tommaso Tabacchi; Giulia Turrini; Mirella Ruggeri; Corrado Barbui
Journal:  PLoS One       Date:  2018-08-02       Impact factor: 3.240

10.  Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians.

Authors:  Leslie Citrome; Emily Belcher; Sylvie Stacy; Mark Suett; Marko Mychaskiw; Gregory D Salinas
Journal:  Neuropsychiatr Dis Treat       Date:  2022-01-26       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.